Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C.

Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok AS, Omary MB; HALT-C Trial Group.

Clin Gastroenterol Hepatol. 2011 Oct;9(10):902-909.e1. doi: 10.1016/j.cgh.2011.07.006. Epub 2011 Jul 23.

2.

Mallory-Denk bodies: Correlation with steatosis, severity, zonal distribution, and identification with ubiquitin.

Kayaçetin S, Başaranoğlu M.

Turk J Gastroenterol. 2015 Nov;26(6):506-10. doi: 10.5152/tjg.2015.150199. Epub 2015 Oct 22.

3.

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group.

Gastroenterology. 2010 Jan;138(1):136-46. doi: 10.1053/j.gastro.2009.09.007. Epub 2009 Sep 18.

4.

The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury.

Hanada S, Strnad P, Brunt EM, Omary MB.

Hepatology. 2008 Sep;48(3):943-52. doi: 10.1002/hep.22436.

PMID:
18697208
5.

Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Aug;137(2):549-57. doi: 10.1053/j.gastro.2009.05.007. Epub 2009 May 13.

6.

From Mallory to Mallory-Denk bodies: what, how and why?

Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, Cadrin M, Omary MB.

Exp Cell Res. 2007 Jun 10;313(10):2033-49. Epub 2007 Apr 27. Review.

PMID:
17531973
7.

Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress.

Hanada S, Snider NT, Brunt EM, Hollenberg PF, Omary MB.

Gastroenterology. 2010 Apr;138(4):1607-17. doi: 10.1053/j.gastro.2009.12.055. Epub 2010 Jan 11.

8.

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865.

9.

Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models.

Chinnaratha MA, Jeffrey GP, MacQuillan G, Rossi E, de Boer BW, Speers DJ, Adams LA.

Liver Int. 2014 May;34(5):720-7. doi: 10.1111/liv.12306. Epub 2013 Sep 4.

PMID:
24034439
10.

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ; HALT-C Trial Group.

Hepatology. 2010 Feb;51(2):585-94. doi: 10.1002/hep.23315.

11.

Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C.

Livingston SE, Deubner H, Bruden DL, McMahon BJ, Homan CE, Townshend-Bulson LJ, Bruce MG, Hennessy TW, Williams JL, Gretch DR.

Can J Gastroenterol. 2010 Jul;24(7):445-51.

12.

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group.

Gut. 2010 Oct;59(10):1401-9. doi: 10.1136/gut.2010.207423. Epub 2010 Jul 30.

13.

Cross β-sheet conformation of keratin 8 is a specific feature of Mallory-Denk bodies compared with other hepatocyte inclusions.

Mahajan V, Klingstedt T, Simon R, Nilsson KP, Thueringer A, Kashofer K, Haybaeck J, Denk H, Abuja PM, Zatloukal K.

Gastroenterology. 2011 Sep;141(3):1080-1090.e1-7. doi: 10.1053/j.gastro.2011.05.039. Epub 2011 May 27.

PMID:
21699779
14.

Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.

Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallée M, Dev A, Smith-Riggs M, McHutchison JG.

Clin Gastroenterol Hepatol. 2008 Feb;6(2):242-7. doi: 10.1016/j.cgh.2007.11.009. Epub 2008 Jan 9.

PMID:
18187364
15.

Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).

Curto TM, Lagier RJ, Lok AS, Everhart JE, Rowland CM, Sninsky JJ; HALT-C Trial group.

Pharmacogenet Genomics. 2011 Dec;21(12):851-60. doi: 10.1097/FPC.0b013e32834c3e74.

16.

Mallory-Denk Bodies in chronic hepatitis.

Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G.

World J Gastroenterol. 2011 May 7;17(17):2172-7. doi: 10.3748/wjg.v17.i17.2172. Review.

17.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.

18.

Dietary cholesterol intake is associated with progression of liver disease in patients with chronic hepatitis C: analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial.

Yu L, Morishima C, Ioannou GN.

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1661-6.e1-3. doi: 10.1016/j.cgh.2013.05.018. Epub 2013 May 23.

PMID:
23707779
19.

Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group.

Gastroenterology. 2011 Sep;141(3):900-908.e1-2. doi: 10.1053/j.gastro.2011.06.007. Epub 2011 Jun 12.

20.

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A.

Am J Gastroenterol. 2008 May;103(5):1136-44. doi: 10.1111/j.1572-0241.2008.01813.x.

PMID:
18477344

Supplemental Content

Support Center